News
Phase II, open-label, randomized study of first-line zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in Claudin 18.2–positive metastatic pancreatic cancer (mPC). Wungki Park , Eileen Mary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback